Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692683 | 0.94 | NOD1 (0.35) | NOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL25773839 | 0.90 | MMP3 (0.32) | MMP3FOLH1 | |
| SCHEMBL20756564 | 0.84 | NOD1 (0.36) | NOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL20643464 | 0.83 | NOD1 (0.36) | NOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL16248525 | 0.83 | NOD1 (0.36) | NOD1KMT2APOLBL3MBTL1MEN1 | |
| SCHEMBL16248526 | 0.83 | NOD1 (0.36) | NOD1KMT2APOLBL3MBTL1MEN1 | |
| SCHEMBL25772845 | 0.81 | NOD1 (0.40) | NOD1KMT2APOLBFOLH1 | |
| SCHEMBL23016490 | 0.81 | NOD1 (0.35) | NOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL24119914 | 0.81 | NOD1 (0.35) | NOD1KMT2APOLBL3MBTL1MEN1 | |
| SCHEMBL18513359 | 0.80 | NOD1 (0.34) | NOD1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | NOD1 4057/4885KMT2A 849/4885POLB 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.